Method for treating hematopoietic neoplasms
View Patent ↗This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.
1. A method of treating a myeloid neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound is combretastatin A-1 diphosphate (CA1dP):
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the combretastatin compound is a pharmaceutically acceptable salt of combretastatin A-1 diphosphate (CA1dP),-wherein the cation of the salt can be either a divalent cation or two monovalent cations.
3. The method of claim 2 , wherein, the divalent cation is a divalent metal cation.
4. The method of claim 2 , wherein, the monovalent cation is an alkali metal, an aliphatic amine or an ammonium.
5. The method of claim 2 , wherein, the monovalent cation is selected from the group consisting of sodium, TRIS, histidine, ethanolamine, diethanolamine, ethylenediamine, diethylamine, triethanolamine, glucamine, N-methylglucamine, ethylenediamine, 2-(4-imidazolyl)-ethylamine, choline, and hydrabamine.
6. The method of claim 1 , wherein the myeloid neoplasm is an acute myeloid leukemia (AML).
7. The method of claim 1 , wherein the myeloid neoplasm is a refractory organ-infiltrating leukemia.
8. The method of claim 1 , wherein the pharmaceutically acceptable salt is a potassium salt of combretastatin A-1 diphosphate.
9. The method of claim 1 , further comprising co-administering a chemotherapeutic agent to the subject having a myeloid neoplasm.
10. The method of claim 9 , wherein the chemotherapeutic agent is Ara-C, etoposide, thioguanine or cyclophosphamide.
11. The method of claim 3 , wherein the divalent metal cation is magnesium or calcium.